Search research articles
Contact Us
Filters
Showing results (351-360 of 493) with videos related to
Page
of 50
Sort By:
Journal of Translational Medicine
|
November 4, 2010
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
Helen Gogas, Urania Dafni, Henry Koon, et al.
The Lancet. Oncology
|
February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Cancer Medicine
|
January 9, 2026
Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Suthee Rapisuwon, Craig L Slingluff, Jennifer A Wargo, et al.
Journal for Immunotherapy of Cancer
|
May 19, 2019
The promise of Immuno-oncology: implications for defining the value of cancer treatment
Howard L Kaufman, Michael B Atkins, Prasun Subedi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 16, 2015
Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer
Liang Zhang, Xiaoen Wang, Andrea J Bullock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2008
Tissue-based research in kidney cancer: current challenges and future directions
Sabina Signoretti, Gennady Bratslavsky, Frederick M Waldman, et al.
Journal for Immunotherapy of Cancer
|
November 20, 2021
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
Meredith M Regan, Charlene M Mantia, Lillian Werner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2016
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma
Martin H Voss, Rupal S Bhatt, Elizabeth R Plimack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2022
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
Thomas Denize, Yue Hou, Jean-Christophe Pignon, et al.
Kidney International
|
May 17, 2013
Divergent functions of the Rho GTPases Rac1 and Cdc42 in podocyte injury
Simone M Blattner, Jeffrey B Hodgin, Masashi Nishio, et al.
Page
of 50
Search research articles
Search
Showing results (351-360 of 493) with videos related to
Sort By:
Page
of 50
Journal of Translational Medicine
|
November 4, 2010
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
Helen Gogas, Urania Dafni, Henry Koon, et al.
The Lancet. Oncology
|
February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Cancer Medicine
|
January 9, 2026
Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Suthee Rapisuwon, Craig L Slingluff, Jennifer A Wargo, et al.
Journal for Immunotherapy of Cancer
|
May 19, 2019
The promise of Immuno-oncology: implications for defining the value of cancer treatment
Howard L Kaufman, Michael B Atkins, Prasun Subedi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 16, 2015
Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer
Liang Zhang, Xiaoen Wang, Andrea J Bullock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2008
Tissue-based research in kidney cancer: current challenges and future directions
Sabina Signoretti, Gennady Bratslavsky, Frederick M Waldman, et al.
Journal for Immunotherapy of Cancer
|
November 20, 2021
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
Meredith M Regan, Charlene M Mantia, Lillian Werner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2016
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma
Martin H Voss, Rupal S Bhatt, Elizabeth R Plimack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2022
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
Thomas Denize, Yue Hou, Jean-Christophe Pignon, et al.
Kidney International
|
May 17, 2013
Divergent functions of the Rho GTPases Rac1 and Cdc42 in podocyte injury
Simone M Blattner, Jeffrey B Hodgin, Masashi Nishio, et al.
Page
of 50